IVERIC bio (ISEE) is an innovative biopharmaceutical company focused on the discovery and development of treatments for retinal diseases with significant unmet medical needs. Stifel has a buy rating on the stock with a $22 price target as it hit an all-time high today. Kymera Therapeutics (KYMR) is a clinical stage biopharmaceutical company. Bank of America recently upgraded the stock to a buy rating with a $80 price target. The final stock that George Tsilis discusses is Rexnord (RXN), an industrial company with a process and motion control platform.